Journal
VACCINE
Volume 39, Issue 11, Pages 1551-1555Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.01.070
Keywords
Vaccination; Streptococcus pneumoniae; Conjugate vaccines; Surveillance; Bias
Categories
Funding
- GlaxoSmithKline
- Pfizer
- Sanofi
Ask authors/readers for more resources
A study showed that there was a significant decline in childhood invasive pneumococcal disease (IPD) in the US after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), with a greater reduction in outpatient IPD compared to hospitalized IPD. In the US, the proportion of hospitalized IPD cases also increased with the introduction of PCV.
High incidence of childhood invasive pneumococcal disease (IPD) in the US declined steeply after 7-valent pneumococcal conjugate vaccine (PCV7) introduction, outweighing reductions observed elsewhere. We re-analysed aggregate published data and compared pre- and post-PCV IPD-incidence in different countries to explore PCV impact on hospitalised and outpatient IPD separately. The proportion of hospitalised IPD cases was consistently high (>80%) in England&Wales, Finland, the Netherlands, and Quebec/Canada, but only 32% in the US before PCV introduction, increasing to 69% during the PCV era. In the US, a higher reduction in outpatient IPD incidence (94% in 2015 versus 1998-99) was observed compared to hospitalised IPD (79%); a 51% reduction in the non-PCV13-type IPD incidence among outpatient cases was estimated compared to a >2-fold increase for hospitalised cases. After stratification by hospitalization status, PCV programmes resulted in similar impact and serotype replacement in hospitalised IPD in US when compared to other countries. Crown Copyright (C) 2021 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available